Department of Surgery, Division of Surgical Oncology, Emory University School of Medicine, Atlanta, GA 30308, USA.
J Am Coll Surg. 2012 Mar;214(3):280-7. doi: 10.1016/j.jamcollsurg.2011.12.005. Epub 2012 Jan 11.
Clinical management of papillary breast lesions (PBLs) remains controversial. The objective of this study was to identify pathologic and radiologic predictors of malignancy from a large cohort of PBLs diagnosed on core-needle biopsy (CNB).
Retrospective review of the institutional pathology database identified all PBLs diagnosed from 2001 to 2009 and surgically excised within 6 months of diagnosis. PBLs were divided into intraductal papilloma (IDP) and IDP associated with atypical ductal or lobular hyperplasia (ADH/ALH). Surgical pathology of all lesions was reviewed and upgrade was defined as a change to a lesion of greater clinical significance, including ALH, ADH, lobular, or ductal carcinoma in situ (LCIS or DCIS), and invasive ducal carcinoma (IDC).
We identified 276 patients (mean age 56 years; range 23 to 88 years) with PBLs on CNB. Seventy-nine patients (28.6%) upgraded to a lesion of greater clinical significance. Of the 234 (84.7%) had IDP only, 42 (17.9%) upgraded to ADH, and 21 (8.9%) to DCIS or IDC. Of the 42 (15.3%) patients with associated ADH or ALH on CNB, 16 (38.0%) upgraded to DCIS or IDC. The majority of patients (n = 173, 62.6%) had no breast symptoms. All patients had an abnormal mammogram and/or ultrasound that prompted the CNB. Among all clinical and radiographic variables analyzed, older age alone was predictive of upgrade.
Frequent upgrade to a high-risk lesion or cancer is observed with IDPs diagnosed on CNB without adequate identifiable clinical and radiographic risk factors. Surgical excision should be performed for all IDPs to delineate subsequent clinical management.
乳头状乳腺病变(PBL)的临床处理仍存在争议。本研究的目的是从大量在核心针活检(CNB)诊断的 PBL 中确定病理和影像学恶性肿瘤的预测因素。
回顾性审查机构病理数据库,确定了所有 2001 年至 2009 年诊断的 PBL,并在诊断后 6 个月内进行手术切除。将 PBL 分为导管内乳头状瘤(IDP)和 IDP 伴非典型导管或小叶增生(ADH/ALH)。所有病变的手术病理均进行了回顾,并将升级定义为病变的临床意义增加,包括 ALH、ADH、小叶或导管原位癌(LCIS 或 DCIS)和浸润性导管癌(IDC)。
我们在 CNB 上确定了 276 例 PBL 患者(平均年龄 56 岁;范围 23 至 88 岁)。79 例(28.6%)升级为更具临床意义的病变。234 例(84.7%)仅有 IDP,42 例(17.9%)升级为 ADH,21 例(8.9%)升级为 DCIS 或 IDC。在 CNB 上有伴发 ADH 或 ALH 的 42 例患者中,16 例(38.0%)升级为 DCIS 或 IDC。大多数患者(n=173,62.6%)无乳房症状。所有患者均有异常的乳房 X 线照片和/或超声,促使进行 CNB。在分析的所有临床和影像学变量中,只有年龄较大是升级的预测因素。
在 CNB 诊断的 IDP 中,观察到经常升级为高危病变或癌症,且无明确的临床和影像学危险因素。应对所有 IDP 进行手术切除,以明确后续的临床管理。